FACE IPF
HEAD ON
and modify disease progression by slowing lung function decline
How to Suspect ILD
01/23/2025 | Author: Boehringer Ingelheim
Document ID: PC-IME-100576 | Expiry Date: 08/29/2026
Related Product Item
OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required
PC-IME-100592 (
)
PPF Diagnosis and Treatment in the Respiratory (ATS/ERS/JRS/ALAT) Guideline
PC-IME-100565 (
)
Risk score for RA-ILD Patient
PC-IME-100562 (
)
